The slides were then scanned using a DNA Microarray Scanner (Model G2505C, Agilent Technologies, USA).
PCR amplifications were performed for 30 cycles using a DNA thermal cycle model 480 (Perkin-Elmer/Cetus, Waltham, MA, USA) in 20 μL reaction mixture containing 0.2 μg of the EcoRI-digested DNA sample in 1× Stoffel fragment buffer, all four deoxyribo-nucleotide triphosphates (each at 0.2 mM), 3 mM MgCl2, 0.2 mM each primer, and 2 U Stoffel fragment enzyme.
In fact, Sun and colleagues have recently demonstrated, using a DNA methylase-deficient cell model, that competition between BORIS and CTCF is a possibility when both proteins are present in equal amounts [6], a situation that may occur in certain cancer cells.
In a mouse model using a DNA vaccine encoding the nucleoprotein (NP) of influenza H1N1, the resulting trend of antibody responses was similar to that detected in guinea pig study.
To the Editor: Less than a year after the identification of the severe acute respiratory syndrome coronavirus (SARS-CoV) (1), 3 independent laboratories reported protection from SARS-CoV challenge in animal models using a DNA vaccine or recombinant forms of the modified vaccinia Ankara or a parainfluenza virus, encoding the spike gene (2– 4).
For all species, PCR amplification was performed in the same laboratory in Sheffield using a DNA Engine Tetrad 2 thermal cycler (model PTC, MJ Research, Bio-Rad, Hemel Hempstead, Herts, UK).
Moreover, we confirmed its immunogenicity by using a mice DNA vaccination model, indicating that DNAJB8 is a promising target of CSC/CIC-targeting immunotherapy.
Intriguingly, however, we observed a striking similarity in the transition lengths obtained for the [GT/CA] motif computationally and experimentally, using a model eukaryotic DNA polymerase.
In addition, a significant correlation was observed of measured binding affinities with binding affinity values predicted using a thermodynamic model involving DNA and RNA unfolding, ODN hybridization, and RNA restructuring to a final free energy minimum.
The SMART assay using a synthetic model influenza DNA target sequence served as a fundamental demonstration of the efficacy of the capture and microfluidic separation system, thus bridging our system to a clinically relevant detection problem.
